^“Hdmx modulates the outcome of p53 activation in human tumor cells”. The Journal of Biological Chemistry281 (44): 33036–44. (November 2006). doi:10.1074/jbc.M605405200. PMID16905769.
^“In vivo activation of the p53 pathway by small-molecule antagonists of MDM2”. Science303 (5659): 844–8. (February 2004). doi:10.1126/science.1092472. PMID14704432.
^ ab“Subcellular localization of beta-arrestins is determined by their intact N domain and the nuclear export signal at the C terminus”. The Journal of Biological Chemistry278 (13): 11648–53. (March 2003). doi:10.1074/jbc.M208109200. PMID12538596.
^“Beta-arrestin 2 functions as a G-protein-coupled receptor-activated regulator of oncoprotein Mdm2”. The Journal of Biological Chemistry278 (8): 6363–70. (February 2003). doi:10.1074/jbc.M210350200. PMID12488444.
^“Cyclin G1 has growth inhibitory activity linked to the ARF-Mdm2-p53 and pRb tumor suppressor pathways”. Molecular Cancer Research1 (3): 195–206. (January 2003). PMID12556559.
^ ab“Hdm2 recruits a hypoxia-sensitive corepressor to negatively regulate p53-dependent transcription”. Current Biology13 (14): 1234–9. (July 2003). doi:10.1016/S0960-9822(03)00454-8. PMID12867035.
^“FKBP25, a novel regulator of the p53 pathway, induces the degradation of MDM2 and activation of p53”. FEBS Letters583 (4): 621–6. (February 2009). doi:10.1016/j.febslet.2009.01.009. PMID19166840.
^“Identification of c-Cbl as a new ligase for insulin-like growth factor-I receptor with distinct roles from Mdm2 in receptor ubiquitination and endocytosis”. Cancer Research68 (14): 5669–77. (July 2008). doi:10.1158/0008-5472.CAN-07-6364. PMID18632619.
^“MdmX is a RING finger ubiquitin ligase capable of synergistically enhancing Mdm2 ubiquitination”. The Journal of Biological Chemistry277 (51): 49668–75. (December 2002). doi:10.1074/jbc.M208593200. PMID12393902.
^“Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans”. Cell Death and Differentiation15 (5): 841–8. (May 2008). doi:10.1038/sj.cdd.4402309. PMID18219319.
^“Mammalian Numb is a target protein of Mdm2, ubiquitin ligase”. Biochemical and Biophysical Research Communications302 (4): 869–72. (March 2003). doi:10.1016/S0006-291X(03)00282-1. PMID12646252.
^“MDM2 inhibits PCAF (p300/CREB-binding protein-associated factor)-mediated p53 acetylation”. The Journal of Biological Chemistry277 (34): 30838–43. (August 2002). doi:10.1074/jbc.M204078200. PMID12068014.
^“Retinoblastoma protein modulates gankyrin-MDM2 in regulation of p53 stability and chemosensitivity in cancer cells”. Oncogene27 (29): 4034–43. (July 2008). doi:10.1038/onc.2008.43. PMID18332869.
^“PML regulates p53 stability by sequestering Mdm2 to the nucleolus”. Nature Cell Biology6 (7): 665–72. (July 2004). doi:10.1038/ncb1147. PMID15195100.
^“MDM2 and promyelocytic leukemia antagonize each other through their direct interaction with p53”. The Journal of Biological Chemistry278 (49): 49286–92. (December 2003). doi:10.1074/jbc.M308302200. PMID14507915.
^“Cellular stress and DNA damage invoke temporally distinct Mdm2, p53 and PML complexes and damage-specific nuclear relocalization”. Journal of Cell Science116 (Pt 19): 3917–25. (October 2003). doi:10.1242/jcs.00714. PMID12915590.
^“Physical and functional interactions between PML and MDM2”. The Journal of Biological Chemistry278 (31): 29288–97. (August 2003). doi:10.1074/jbc.M212215200. PMID12759344.
^“The MDM2 C-terminal region binds to TAFII250 and is required for MDM2 regulation of the cyclin A promoter”. The Journal of Biological Chemistry272 (49): 30651–61. (December 1997). doi:10.1074/jbc.272.49.30651. PMID9388200.
“Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53”. The Journal of Biological Chemistry275 (12): 8945–51. (March 2000). doi:10.1074/jbc.275.12.8945. PMID10722742.
“Functions of the MDM2 oncoprotein”. Cellular and Molecular Life Sciences55 (1): 96–107. (January 1999). doi:10.1007/s000180050273. PMID10065155.
“Multiple sites of in vivo phosphorylation in the MDM2 oncoprotein cluster within two important functional domains”. FEBS Letters478 (1–2): 183–6. (July 2000). doi:10.1016/S0014-5793(00)01850-0. PMID10922493.
“Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase”. Oncogene19 (11): 1473–6. (March 2000). doi:10.1038/sj.onc.1203464. PMID10723139.
“Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain”. Science274 (5289): 948–53. (November 1996). doi:10.1126/science.274.5289.948. PMID8875929.
“Posttranslational modification of MDM2”. Molecular Cancer Research1 (14): 1017–26. (December 2003). PMID14707285.
“An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo”. Oncogene19 (19): 2312–23. (May 2000). doi:10.1038/sj.onc.1203593. PMID10822382.
“The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation”. Cell69 (7): 1237–45. (June 1992). doi:10.1016/0092-8674(92)90644-R. PMID1535557.